Forum · Medicine · Story discussion
Tau Therapy Shows Continued Benefit at 2 Years in Alzheimer's
(MedPage Today) -- Diranersen, an investigational antisense oligonucleotide therapy that targets tau, continued to show benefits for 96 weeks, data from the open-label extension of the phase II CELIA trial suggested. At…
2 days ago — MedPage Today · Read the original
Peer reviews (0)
Comments (0)
No comments yet. Start the discussion.
Loading sign-in…